http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2424796-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6379feda6e2eb9af0653088fc5870448
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
filingDate 2010-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2011-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aef109eac4b63901ae49efb01678cd62
publicationDate 2011-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2424796-C1
titleOfInvention Method of treating toxic optic neuropathy, induced by long intake of codeine-containing medications
abstract FIELD: medicine. n SUBSTANCE: invention relates to medicine, in particular to ophthalmology, and deals with treatment of toxic optic neuropathy, induced by long intake of codeine-containing medications. For this purpose, as the first stage, carried out is complex treatment for 10 days by intravenous introduction of medication nootropyl in dose 5-10 ml, intramuscular introduction of medication glutoxim 2.0 ml, milgamma 2.0 ml, parabulbar introduction of dexason 0.5 ml, introduction of heptral in dose I tablet 3 times per day and 10 sessions of transcutaneous electrostimulation of optic nerves, starting from the first day, I session per day, then starting from the 11-th day, as the second stage, for the following 10 days carried out are intravenous introduction of cerebrolysin 5-10 ml, intramuscular introduction of proserin 0.5-1.0 ml, mexidol 1.0-2.0 ml daily, parabalbar introduction of emoxipin 0.5 ml, introduction of pantogam 0.25 g 3 times per day, as well as carrying out 10 sessions of magnetic stimulation of optic nerves, starting from the 11-th day from beginning of treatment, one session per day. n EFFECT: increase of visual functions in case of said pathology. n 2 ex, 1 tbl
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2494775-C1
priorityDate 2010-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID408264951
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493326
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419493286
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419506254
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284596
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID45934189
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5492635
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID114681
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID522325
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491632
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4456
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451620331
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3032771
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501369
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419491720
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6009
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419501353
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID452639634
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4843
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID28280
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448561562
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4763
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492800
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497675

Total number of triples: 44.